High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area
Résumé
Objectives: We studied the kinetics of SARS-CoV-2 antibodies and identified the associated risk factors with the presence of these antibodies.
Methods: In this longitudinal cohort study, we included all PLWHIV. Samples were tested for IgG targeting the nucleocapsid (N) and all positive samples were tested for IgG targeting the spike (S) and IgA targeting S.
Results: 1,901 PLWHIV were included: 64.4% male, median age: 53 years (44-60). At inclusion, 254 (13.4%, 95% CI 11.9, 15.0) had positive IgG anti-N. Levels of IgG anti-N, IgG anti-S and IgA anti-S were 3.95 (standard error: 0.16), 199.4 BAU/mL (21.7) and 3.14 (0.21), respectively. Over one year, levels of IgG anti-N and anti-S decreased significantly (-2.83 p<0.0001 and -94.9 BAU/mL p= 0.0010, respectively), while IgA level increased significantly (+2.97 p=0.0032). Multivariable analysis showed that Sub-Saharan African patients were more likely to have positive IgG anti-N in comparison with other patients (OR:4.78 (95% CI 3.39, 6.73), p<0.0001), while active smoking was a protective factor (OR: 0.57 (95% CI 0.36, 0.90), p=0.0176).
Conclusion: We showed in these PLWHIV a high SARS-CoV-2 seroprevalence. A higher seroprevalence was observed in sub-Saharan Africa patients, probably due to socioeconomic status and a lower seroprevalence was observed in active smokers
Fichier principal
High SARS-CoV-2 seroprevalence in HIV patients - VF- HAL.pdf (420.92 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)